Terms: = Ovarian cancer AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Clinical Outcome
53 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. A methylation- and immune-related lncRNA signature to predict ovarian cancer outcome and uncover mechanisms of chemoresistance.
Chen L; Gao W; Lin L; Sha C; Li T; Chen Q; Wei H; Yang M; Xing J; Zhang M; Zhao S; Xu W; Li Y; Long L; Zhu X
J Ovarian Res; 2023 Sep; 16(1):186. PubMed ID: 37674251
[TBL] [Abstract] [Full Text] [Related]
3. VSTM2L contributes to anoikis resistance and acts as a novel biomarker for metastasis and clinical outcome in ovarian cancer.
Li Y; Zhang J; Cai Y; Liu H; Yang W; Xu Y; Huang M
Biochem Biophys Res Commun; 2023 May; 658():107-115. PubMed ID: 37030064
[TBL] [Abstract] [Full Text] [Related]
4. Overexpression of LILRA2 indicated poor prognosis of ovarian carcinoma: A new potential biomarker and therapeutic target.
Zhang Y; Zhang L; Zhao Y; Wang S; Feng L
Taiwan J Obstet Gynecol; 2023 Jan; 62(1):77-88. PubMed ID: 36720556
[TBL] [Abstract] [Full Text] [Related]
5. Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer.
Gao J; Zhao Z; Zhang H; Huang S; Xu M; Pan H
Cancer Immunol Immunother; 2023 May; 72(5):1121-1138. PubMed ID: 36336725
[TBL] [Abstract] [Full Text] [Related]
6. cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
Yu S; Yang R; Xu T; Li X; Wu S; Zhang J
Gynecol Oncol; 2022 Nov; 167(2):342-353. PubMed ID: 36114029
[TBL] [Abstract] [Full Text] [Related]
7. Proposing a molecular classification associated with hypercoagulation in ovarian clear cell carcinoma.
Tamura R; Yoshihara K; Matsuo K; Yachida N; Miyoshi A; Takahashi K; Sugino K; Yamaguchi M; Mori Y; Suda K; Ishiguro T; Okuda S; Motoyama T; Nakaoka H; Kikuchi A; Ueda Y; Inoue I; Enomoto T
Gynecol Oncol; 2021 Nov; 163(2):327-333. PubMed ID: 34452748
[TBL] [Abstract] [Full Text] [Related]
8. Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma.
Matsushita H; Hasegawa K; Oda K; Yamamoto S; Asada K; Karasaki T; Yabuno A; Nishijima A; Nejo T; Kobayashi Y; Sato S; Ikeda Y; Miyai M; Takahashi Y; Yamaguchi R; Fujiwara K; Aburatani H; Kakimi K
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461346
[TBL] [Abstract] [Full Text] [Related]
9. Expression of ACAP1 Is Associated with Tumor Immune Infiltration and clinical outcome of ovarian cancer.
Zhang J; Zhang Q; Zhang J; Wang Q
DNA Cell Biol; 2020 Sep; 39(9):1545-1557. PubMed ID: 32456571
[TBL] [Abstract] [Full Text] [Related]
10. Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome.
Reijnen C; Küsters-Vandevelde HVN; Ligtenberg MJL; Bulten J; Oosterwegel M; Snijders MPLM; Sweegers S; de Hullu JA; Vos MC; van der Wurff AAM; van Altena AM; Eijkelenboom A; Pijnenborg JMA
Int J Cancer; 2020 Jul; 147(2):478-489. PubMed ID: 32022266
[TBL] [Abstract] [Full Text] [Related]
11. High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome.
Wolf D; Fiegl H; Zeimet AG; Wieser V; Marth C; Sprung S; Sopper S; Hartmann G; Reimer D; Boesch M
Int J Cancer; 2020 Apr; 146(7):2007-2018. PubMed ID: 31800094
[TBL] [Abstract] [Full Text] [Related]
12. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract] [Full Text] [Related]
13. Seven Genes Based Novel Signature Predicts clinical outcome and Platinum Sensitivity of High Grade IIIc Serous ovarian Carcinoma.
Liu G; Chen L; Ren H; Liu F; Dong C; Wu A; Liu Z; Zheng Y; Cheng X; Liu L
Int J Biol Sci; 2018; 14(14):2012-2022. PubMed ID: 30585265
[No Abstract] [Full Text] [Related]
14. Identification of pathway-based recurrence-associated signatures in optimally debulked patients with serous ovarian cancer.
Deng K; Zhang F; Song W; Zhao W; Rong Z; Cai Y; Xu H; Lu M; Wang W; Li A; Hou Y; Li Z; Li K
J Cell Biochem; 2018 Nov; 119(10):8564-8573. PubMed ID: 30126000
[TBL] [Abstract] [Full Text] [Related]
15. Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial ovarian Carcinoma.
Fridley BL; Dai J; Raghavan R; Li Q; Winham SJ; Hou X; Weroha SJ; Wang C; Kalli KR; Cunningham JM; Lawrenson K; Gayther SA; Goode EL
Cancer Epidemiol Biomarkers Prev; 2018 Sep; 27(9):1101-1109. PubMed ID: 29967001
[No Abstract] [Full Text] [Related]
16. Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological cancers.
Nielsen B; Kleppe A; Hveem TS; Pradhan M; Syvertsen RA; Nesheim JA; Kristensen GB; Trovik J; Kerr DJ; Albregtsen F; Danielsen HE
J Natl Cancer Inst; 2018 Dec; 110(12):1400-1408. PubMed ID: 29684152
[TBL] [Abstract] [Full Text] [Related]
17. Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer.
Martínez-Canales S; López de Rodas M; Nuncia-Cantarero M; Páez R; Amir E; Győrffy B; Pandiella A; Galán-Moya EM; Ocaña A
Cancer Med; 2018 May; 7(5):1896-1907. PubMed ID: 29575713
[TBL] [Abstract] [Full Text] [Related]
18. Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With clinical outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.
Niu H; Shin H; Gao F; Zhang J; Bahamon B; Danaee H; Melichar B; Schilder RJ; Coleman RL; Falchook G; Adenis A; Behbakht K; DeMichele A; Dees EC; Perez K; Matulonis U; Sawrycki P; Huebner D; Ecsedy J
EBioMedicine; 2017 Nov; 25():50-57. PubMed ID: 29122619
[TBL] [Abstract] [Full Text] [Related]
19. A network-pathway based module identification for predicting the prognosis of ovarian cancer patients.
Wang X; Wang SS; Zhou L; Yu L; Zhang LM
J Ovarian Res; 2016 Nov; 9(1):73. PubMed ID: 27806724
[TBL] [Abstract] [Full Text] [Related]
20. Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer.
Raghavan R; Hyter S; Pathak HB; Godwin AK; Konecny G; Wang C; Goode EL; Fridley BL
BMC Genomics; 2016 Oct; 17(1):811. PubMed ID: 27756228
[TBL] [Abstract] [Full Text] [Related]
[Next]
